CTD and eCTD Requirements for HSA Submissions in 2025


CTD and eCTD Requirements for HSA Submissions in 2023

Published on 22/12/2025

CTD and eCTD Requirements for HSA Submissions in 2023

In the highly regulated pharmaceutical landscape, the process of drug registration and market authorization can be daunting. The Health Sciences Authority (HSA) of Singapore mandates specific requirements for Common Technical Document (CTD) and electronic Common Technical Document (eCTD) submissions. This article provides a comprehensive, step-by-step guide designed for regulatory affairs professionals navigating the complexities of the Singapore HSA regulatory framework.

Step 1: Understanding the Regulatory Framework of HSA

Before engaging in the submission process, it is crucial to comprehend the regulatory landscape in Singapore. The HSA oversees the safety, quality, and efficacy of health products, including pharmaceuticals, biologics, and medical devices. The foundation of HSA’s regulatory framework is guided by international standards, which include the ICH Guidelines, ensuring a global harmonization of pharmaceutical regulatory practices.

The HSA focuses on evaluating applications through a rigorous assessment process that includes pre-assessment, evaluation, and post-market surveillance. Understanding these phases ensures that applicants can

adequately prepare and submit documentation aligned with HSA expectations.

First, familiarize yourself with the key documents pertaining to HSA submissions, including:

  • The Medicines Act
  • Guidelines on the Submission of Applications for Product Registration
  • HSA’s eCTD Submission Guidelines
  • Other relevant ICH guidelines

Documentation Expectations: Applicants should compile a dossier including clinical data, quality information, and preclinical studies demonstrating the product’s safety and efficacy. For optimal compliance, it is advisable to consult the HSA website for the most up-to-date documentation guidelines.

Step 2: Preparing the Common Technical Document (CTD)

The Common Technical Document is a standardized format for the preparation of applications and submissions across territories. It comprises five main modules, which must be completed to make an effective submission to the HSA.

Module 1: Administrative Information

This module includes details about the applicant and administrative aspects of the application. Failure to provide accurate information may lead to delays in processing. Ensure your contact details, product name, dosage form, and indication are correct.

Also Read:  ASEAN Harmonization Impact on Philippines Drug Approvals in 2025

Module 2: Summaries

In this module, the quality overall summary, non-clinical overview, and clinical overview must be succinct yet comprehensive. Summarize how the presented data supports the application’s claims regarding quality, safety, and efficacy.

Module 3: Quality

Detailed data on the drug substance and drug product, including manufacturing processes, quality control methods, and stability data, are required. This module must align with the guidelines established by HSA and any relevant ICH specifications.

Module 4: Non-Clinical Study Reports

Conduct an exhaustive review of preclinical studies, including toxicity, pharmacology, and pharmacokinetics. Detailed reports provide insight into the product’s safety profile and justifies its clinical use.

Module 5: Clinical Study Reports

This module should detail the clinical studies conducted, including study designs, statistical analyses, and results. Highlight the safety and efficacy data collected to support market authorization. Ensure compliance with GCP guidelines throughout.

Documentation Expectations: Ensure all modules are accurately completed and reviewed. It is recommended to utilize templates for each section to facilitate consistency and accuracy. Apply high standards of documentation and integrity, as discrepancies may lead to application rejection.

Step 3: Transitioning to Electronic Submissions (eCTD)

The eCTD format has become the industry standard for regulatory submissions. It streamlines the submission process and enhances efficiency in application management and review. The HSA encourages the use of eCTD for all submissions. Your submission in eCTD format must follow the set requirements meticulously.

Preparing the eCTD: The eCTD submission consists of structured modules similar to the CTD, but it must be organized into an electronic format that meets HSA specifications.

  • File Naming: Properly name each file according to specifications provided in the eCTD guidelines. Consistent naming patterns ensure easy navigation and retrieval of submitted documents.
  • PDF Formatting: All documents must be in PDF format. They should be text-searchable to facilitate review processes initiated by the HSA. Avoid password-protected files.
  • Submission via ePortfolio: All submissions must be sent through the HSA’s ePortfolio system. Familiarize yourself with the system’s functionalities to ensure successful submissions.

Documentation Expectations: Regularly validate and test your eCTD submission packages. Use appropriate software tools to ensure compliance and accuracy. Scheduled training sessions on eCTD preparation and submission may enhance the team’s technical competence.

Also Read:  HSA Requirements for Biosimilars and Advanced Therapies in 2025

Step 4: Submission of Applications to HSA

Once the CTD/eCTD is prepared, the next phase involves the official submission to HSA. This phase is critical, where non-compliance or errors can delay approval timelines. Understanding HSA’s online submission processes is paramount.

Creating an Online Account: Register for an HSA account if not already done. This account will serve as your gateway to submit applications. Clear registration procedures are outlined on the HSA website.

Filing the Application: During the submission process, ensure that:

  • All sections of the application are complete, including relevant supplementary forms.
  • Fees associated with the submission are paid. Each application type has different fee structures, which should be checked and prepared beforehand.
  • All supporting documents are included per the requirements outlined in the preceding steps.

Review Status Tracking: After submitting the application, use the HSA’s tracking system to monitor the application’s progress. This tool typically provides insights into any issues or additional requirements needed.

Documentation Expectations: Develop a submission checklist to ensure all components required by the HSA are included. Establish who will be responsible for monitoring and addressing submission status updates regularly.

Step 5: HSA Review Process and Responding to Queries

HSA undertakes a systematic review process for all applications received. Understanding this process helps prepare for potential inquiries from the HSA that may arise during their assessment.

Evaluation Criteria: The application will be evaluated based on the completeness of the submission, ensuring adherence to regulatory guidelines, and the safety and efficacy data provided. This part may include:

  • Clinical evaluations
  • Scientific quality checks of submitted materials
  • Quality audits (where applicable)

Responding to Queries: If HSA identifies any deficiencies during the review phase, they will contact the applicant for clarifications. Prepare to address these queries succinctly and professionally. Recommendations include:

  • Assign specific team members to manage inquiries.
  • Develop template responses for common queries to streamline the response process.
  • Maintain a log of submitted queries and resolutions for future reference.

Documentation Expectations: Ensure a clear internal communication framework is established so that all team members are updated on issues raised by HSA and responses submitted. Maintain records of all correspondence related to the evaluation process.

Also Read:  Post-Approval Variations and Change Management in 2025

Step 6: Post-Approval Commitments and Market Authorization Oversight

Upon successful evaluation and subsequent approval by the HSA, adherence to post-approval commitments is essential. This phase signifies the ongoing responsibility of obtaining and maintaining market authorization.

Post-Approval Studies: Often, the HSA may require further studies post-approval to monitor long-term safety and efficacy. Develop a robust plan and timeline to conduct these studies efficiently. Regular reporting may be mandated, including:

  • Periodic Safety Update Reports (PSURs)
  • Risk Evaluation and Mitigation Strategies (REMS)

Commitment to Reporting: Following market authorization, it is critical to report any adverse events or quality issues to HSA promptly. Failure to adhere to these requirements can lead to penalties or revocation of market authorization.

Documentation Expectations: Create a post-marketing surveillance plan that outlines mandatory reporting timelines and responsibilities. All data must be systematically documented and analyzed to ensure compliance with HSA’s ongoing regulatory requirements.